Reuters
30 Jul 2026, 08:06 UTC · 14w ago
UCB shares fall despite guidance upgrade as investors question earnings quality
Impact · against what's priced in
UCB faces a valuation headwind as the underperformance of its flagship drug Bimzelx outweighs a guidance upgrade. The market is discounting the raised earnings projections due to concerns over the quality of those gains.
- UCB−0.40
No priced-in read yet
- In context
Weaker-than-expected sales for Bimzelx undermine the company's core growth engine, while skepticism regarding the quality of the 2026 earnings upgrade prevents the guidance raise from acting as a positive catalyst.
Read from the article alone
Top 2 movers · tap to explore
